与AQP4-IgG或MOG-IgG同时存在的GFAP-IgG患者的临床特征
1Department of Neurology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Frontiers in immunology
|August 8, 2025
概括
状纤维酸性蛋白-免疫球蛋白G (GFAP-IgG) 可以与水-4-IgG (AQP4-IgG) 或髓寡细胞糖蛋白-IgG (MOG-IgG) 共存. 患有重叠GFAP-IgG综合征的患者表现出明显的临床特征,GFAP-MOG重叠更经常出现发作.
科学领域:
- 神经免疫学 神经免疫学
- 神经学 神经学
- 自免疫性疾病 自免疫性疾病
背景情况:
- 状纤维酸性蛋白-免疫球蛋白G (GFAP-IgG) 可以与水-4-IgG (AQP4-IgG) 或髓寡细胞糖蛋白-IgG (MOG-IgG) 一起发生.
- 研究这些共存的条件对于理解各种自身免疫神经系统疾病至关重要.
研究的目的:
- 研究与AQP4-IgG或MOG-IgG共存的GFAP-IgG患者的临床特征.
- 为了比较重叠的GFAP-IgG综合征与非重叠病例的临床表型.
主要方法:
- 从81名GFAP-IgG阳性患者回顾性数据收集.
- 对重叠 (GFAP-IgG/AQP4-IgG或GFAP-IgG/MOG-IgG) 和非重叠的GFAP-IgG综合征之间的临床特征的描述和比较.
主要成果:
- 九名患者 (11.1%) 患有GFAP-IgG/AQP4-IgG,七名患者 (8.6%) 患有GFAP-IgG/MOG-IgG.
- 与GFAP-AQP4重叠 (0%) 相比,GFAP-MOG重叠综合征显示了更高的发作频率 (57.1%).
- 叠加综合征与更多的女性有关,视神经炎的发病率更高,CSF白细胞数量和蛋白质水平较低,长期免疫疗法使用增加.
结论:
- 大约20%的患有自身免疫GFAP星病变 (A-GFAP-A) 的患者同时具有AQP4-IgG或MOG-IgG.
- 这些重叠的疾病具有明显的临床特征,表明独特的自身免疫病理机制.
更多相关视频
09:29Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
Published on: August 21, 2017
11.6K
06:35An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
Published on: February 8, 2019
7.3K
相关概念视频
Myasthenia Gravis: Diagnostic Tests
1.3K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.3K
Myasthenia Gravis: Overview and Treatment
1.9K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.9K
